Literature DB >> 25842086

Comments on "Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial".

Martin Schlumberger1.   

Abstract

Entities:  

Keywords:  Refractory thyroid cancer; sorafenib

Year:  2014        PMID： 25842086     DOI： 10.3978/j.issn.2304-3865.2014.01.02

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN： 2304-3865


× No keyword cloud information.
  6 in total

1.  Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report.

Authors:  Li Jin Duo; Jiang Rong; Wang Bin; Ma Chun Hua; Sun Li Wei; L V Yuan
Journal:  Oncol Lett       Date:  2015-05-04       Impact factor: 2.967

Review 2.  Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

3.  Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.

Authors:  Keith C Bible; Gilbert J Cote; Michael J Demeure; Rossella Elisei; Sissy Jhiang; Matthew D Ringel
Journal:  J Clin Endocrinol Metab       Date:  2015-09-29       Impact factor: 5.958

4.  Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.

Authors:  Ramona Dadu; Catherine Devine; Mike Hernandez; Steven G Waguespack; Naifa L Busaidy; Mimi I Hu; Camilo Jimenez; Mouhammad A Habra; Rena V Sellin; Anita K Ying; Gilbert J Cote; Steven I Sherman; Maria E Cabanillas
Journal:  J Clin Endocrinol Metab       Date:  2014-03-14       Impact factor: 5.958

5.  Heart failure as first sign of development of cardiac metastases in a patient with diagnosis of papillary thyroid carcinoma on treatment with tyrosine-kinase inhibitors: differential diagnoses and clinical management.

Authors:  Gema Bruixola; Angel Segura; Javier Caballero; Ana Andrés; Encarnación Reche; Corina Escoín; Roberto Díaz-Beveridge
Journal:  Case Rep Oncol       Date:  2014-08-20

6.  Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib.

Authors:  Syed Zubair Hussain; Ali Asghar; Mubasher Ikram; Najmul Islam
Journal:  BMC Endocr Disord       Date:  2013-08-09       Impact factor: 2.763
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.